1.1Inhibitor inside lipid vesicles
A phospholipid and cholesterol bilayer encloses dissolved topoisomerase inhibitor. The vesicles circulate after intravenous infusion and release small molecules that enter tumor cells.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
A phospholipid and cholesterol bilayer encloses dissolved topoisomerase inhibitor. The vesicles circulate after intravenous infusion and release small molecules that enter tumor cells.
The dry conjugate has no fixed counterion or solvent stoichiometry. A sterile histidine buffer and sucrose support dissolution and protein stability during preparation of the infusion.
A biodegradable polyanhydride wafer placed against the wall of a tumor resection cavity contains dispersed inhibitor. Hydrolysis erodes the wafer and releases inhibitor that diffuses into adjacent tissue.
A glucuronide group masks a hydroxyl on a topoisomerase inhibitor precursor. In tumors with extracellular beta-glucuronidase activity, hydrolysis releases the active small molecule, which enters nearby cells.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
Use the ligand–drug conjugate as a test article in an analytical assay. Incubate the conjugate with a lysosomal protease preparation and sample the mixture over time. Quantify the released topoisomerase inhibitor by liquid chromatography–mass spectrometry using the free inhibitor as a calibration reference. Run a matched incubation without protease to measure background release.
Dispense 50 µL aliquots of conjugate at 0.2 mg/mL into sealed low-binding wells. Hold replicate aliquots at 4 °C and 37 °C and collect separate wells at 0, 6, 24, and 48 hours. Measure soluble aggregates by size-exclusion chromatography and released inhibitor by liquid chromatography–mass spectrometry. Compare each measurement with the initial sample at the same temperature.
Place antigen-expressing tumor spheroids in the central chamber of a microfluidic culture chip and perfuse conjugate-containing medium through an adjacent channel. A porous barrier between the channel and chamber permits transport into the spheroid compartment. After the exposure interval, switch to conjugate-free medium and collect the outlet fractions for inhibitor quantification. Image a labeled fraction of the conjugate in the spheroids and run a matched chip with antigen-negative spheroids.
Feed intact conjugate mass spectra into software that deconvolutes the charge-state envelope into neutral masses. Assign peaks by matching the unconjugated ligand mass plus integer multiples of the net mass added by each drug linker, accounting for known ligand glycoforms. Report the relative abundance of each loading state and calculate the mean loading from the assigned peak areas. Flag unresolved assignments for manual review.
Use a beta-D-glucuronide trigger in place of the peptide trigger. Connect the glucuronide through its anomeric oxygen to the phenolic oxygen of a self-immolative benzyl spacer, and attach the spacer to the inhibitor amino group through a carbamate. Connect a separate handle on the glucuronide-bearing linker to the ligand. Beta-glucuronidase removes the sugar and exposes the phenol, triggering spacer fragmentation and release of the free inhibitor amine.
One ligand unit carries two covalently attached drug linker units, giving p = 2. Intact mass spectrometry distinguishes the two-unit conjugate from species with other loading levels.
An immunoglobulin ligand binds an internalizing receptor on the tumor cell surface. Receptor-mediated endocytosis transports the bound conjugate through endosomes toward lysosomes, where linker cleavage releases the inhibitor.
The drug linker unit attaches through the inhibitor derivative’s amino group. Cleavage at the drug-side attachment restores the free amino group on the released inhibitor.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
An antibody drug conjugate (ADC) having a structure of Formula I AbL1-L2-D)n (I) or a pharmaceutically acceptable salt thereof, wherein: Ab is an antibody;A · US 2017/0224835 A1 · claim 1
Linkers that can be used to conjugate an antibody, antigen-binding fragment thereof, or ligand to a cytotoxic agent include those that are covalently bound to the cytotoxic agent on one end of the linker and, on the other end of the linker, contain a chemical moiety formed from a coupling reaction between a reactive substituent present on the linker and a reactive substituent present within the antibody, antigen-binding fragment thereof, or ligand that binds CD137.B · US 2018/0289832 A1 · ¶ 349
Exemplary antibody-drug conjugates and ligand-drug conjugates useful in conjunction with the methods described herein may be formed by the reaction of an antibody, antigen-binding fragment thereof, or ligand with an amatoxin that is conjugated to a linker containing a substituent suitable for reaction with a reactive residue on the antibody, antigen-binding fragment thereof, or ligand.B · US 2018/0289832 A1 · ¶ 346
An empty cell means only that no passage was reproduced there.
The present disclosure provides anthracycline derivative active agent (drug moiety) antibody conjugates (ADCs) that provide improved safety and cell killing efficacy by substituting a hydroxymethyl ketone moiety for a hydrazide or hydroxamate moiety on a basic anthracycline pharmacophore.A · US 2017/0224835 A1 · ¶ 2
The disclosed modifications provide cytotoxic agents that are conjugated to an antibody via either Cys or Lys.A · US 2017/0224835 A1 · ¶ 2
Thus, there is a need to develop a strategy to more specifically target the cellular mediators of both GVHD and autoimmune diseases.B · US 2018/0289832 A1 · ¶ 5
This selective depletion of T cells in turn improves overall and relapse-free patient survival while significantly decreasing GVHD and autoimmune diseases.B · US 2018/0289832 A1 · ¶ 6
patent.fyi, US 2026/0356844 A1, claim 1, first published 2026-11-20T08:11:50-05:00, https://patent.fyi/US20260356844/, SHA-256 2558fda39c37d7a71c60b4f4a288d64c129d15510d9bb9233ba5a1882d69a152